Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health. Our team works collaboratively and relentlessly to advance our therapies with the goal of improving the lives of patients, their families, and their caregivers. The Radius portfolio consists of commercial and clinical development assets that include mid to late-stage drug candidates.
We are dedicated to serving those patients suffering from bone loss like the 8.9 million osteoporotic fractures that occur annually worldwide1. In 2017, we launched our first commercial product in the U.S., TYMLOS® (abaloparatide injection), for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Abaloparatide-SC (subcutaneous injection) is being developed for the potential treatment of men with osteoporosis, and abaloparatide-TD (transdermal system) is being developed for the potential treatment of postmenopausal women with osteoporosis. In the fourth quarter of 2021 Radius announced topline results from both Phase 3 clinical trials.
The Radius clinical pipeline includes the investigational drug elacestrant being developed for the potential treatment of patients with ER+ breast cancer. In July 2020, Radius entered into an exclusive global license agreement with Menarini Group for the development and commercialization of elacestrant, an investigative oral selective estrogen receptor degrader (SERD). In October 2021, the companies jointly announced positive topline results from the Phase 3 trial (EMERALD) evaluating elacestrant as a hormonal treatment for postmenopausal breast cancer.
1 Source: International Osteoporosis Foundation